Salicylic acid 1% / Lactic acid 2% in Generic Unguentum M cream
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Salicylic acid + Lactic acid
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Part of the Bazuka brand family (generic: Salicylic acid + Lactic acid)
MHRA licensed products
View all licensed products for Salicylic acid + Lactic acid on the MHRA register
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 4 · Randomised trials: 3 · 1991–2026
Showing the 50 most relevant studies, sorted by most relevant.
C. Cherrington, M. Hinton, G. Mead, et al.
Advances in microbial physiology, 1991
Zhou Li, J. Yu, Yan Peng, et al.
Physiologia plantarum, 2017
Z. B. Pario, L. R. Visitacion, B. S. Pandita-Reyes
Journal of the Philippine Dermatological Society, 2023
Șoimița Emiliana Măgerușan, G. Hancu, Aura Rusu
Molecules, 2023
A. Broberg, K. Jacobsson, K. Ström, et al.
Applied and Environmental Microbiology, 2007
Bushra Rehman Niazi, Farid ur Rehman
Journal of Pakistan Association of Dermatologists, 2018
Objective To compare the efficacy of 20% zinc oxide paste versus 15% salicylic acid-15% lactic acid combination in treatment of common viral warts. Methods In this randomized controlled trial, 210 patients suffering from common warts for more than three months duration were enrolled. These patients were randomly divided into two groups A and B; having 105 each. Group A patients were treated with topical 20% zinc oxide paste, whereas group B were treated with 15% salicylic-15% lactic acid combination. Patients were instructed to apply medication for 15 minutes, let it dry and then rub the wart with an emery stone before the next application. Patients were reviewed monthly for a period of three months to examine the change in number and size of warts. Efficacy of treatment was defined as more than 50% decrease in size of common warts at the end of 3 months of therapy. Results Efficacy was achieved in 65 (61.9%) patients of group B (15% salicylic acid-15% lactic acid combination) as compared to 48 (45.7%) patients group A (20 % zinc oxide paste), which was statistically significant (p< 0.05). Conclusion Topically applied 15% salicylic acid-15% lactic acid combination is superior in efficacy to 20% zinc oxide paste in treatment of common viral warts.
Abstract licence: CC BY 4.0
Almeman AA
2024
The global market for alpha-hydroxy acids (AHAs) is undergoing significant expansion, propelled by increasing demand for skincare products that address aging and environmental damage. This review focuses on the dermatological applications of AHAs, particularly in cosmetic formulations like chemical peels. We have identified that AHAs, such as glycolic and lactic acids, enhance skin rejuvenation by promoting apoptosis in skin cells, boosting collagen and elastin synthesis, and improving skin texture and luminosity. Our comprehensive analysis reveals a nuanced understanding of AHAs' effectiveness across various skin types and conditions, demonstrating their broad utility in treating conditions like acne, hyperpigmentation, and photoaging. However, the optimal concentrations for therapeutic efficacy with minimal side effects are yet to be precisely defined, necessitating further research. Regulatory compliance is underscored as essential for the safe application of AHAs in cosmetics, with international guidelines recommending specific concentrations and pH levels to minimize potential skin irritation. In Conclusion, the review highlights the effectiveness of AHAs in cosmetic dermatology, emphasizing the necessity for continued research and rigorous regulatory adherence to maximize their safe and beneficial application worldwide.
Abstract licence: CC BY-NC
Zabihollah Shahmoradi, Fatimah Assaf, Hassan Al Said, et al.
Advanced Biomedical Research, 2015
D. Kligman, A. Kligman
Dermatologic Surgery, 1998
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.